Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
Gilead's $2.2B Ouro buy delivers TCE, new purpose for Galapagos
Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.
James Waldron
Mar 24, 2026 3:34am
Sanofi returns to TCEs via $1.2B pact for ph.1-stage trispecific
Mar 23, 2026 9:27am
Crossbow hits $77M series B round to bankroll quiver of T-Bolts
Mar 18, 2026 10:50am
UCB enters TCE space with $1.1B deal for autoimmune candidate
Mar 4, 2026 8:20am
Candid scores Nasdaq listing via reverse merger Rallybio
Mar 2, 2026 11:45am
BioNTech’s B7-H3 ADC hits ph. 3 at half the size of Merck’s
Feb 27, 2026 10:31pm
